US 10342786
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted A61KA61K31/416A61K31/437
Quick answer
US patent 10342786 (P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD) held by Fulcrum Therapeutics, Inc. expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Fulcrum Therapeutics, Inc.
- Grant date
- Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/416, A61K31/437, A61K31/4418, A61K31/4439